

## TITLE PAGE

### European Journal of Obstetrics and Gynecology and Reproductive Biology: Letter to the Editor

#### Title:

Proposal for a new ICD-11 coding classification system for endometriosis

#### Authors and Societal Representation(s):

*Dr Lucy Whitaker (Clinical Lecturer and Clinical Fellow in Advanced Laparoscopic Surgery, UK)*  
Society of Endometriosis and Uterine Disorders (SEUD) Communications Committee Member  
World Endometriosis Society (WES) Junior Board Member

*Mr Dominic Byrne (Endopelvic Surgeon, UK)*  
Past President of the British Society for Gynaecological Endoscopy (BSGE), Member of the National Institute of Clinical Excellence (NICE) Guideline Group for Endometriosis

*Ms Lone Hummelshoj (Endometriosis Advocate, UK)*  
Chief Executive of the World Endometriosis Society (WES), Chief Executive of the World Endometriosis Research Foundation (WERF), Publisher/Editor-in-Chief of Endometriosis.org

*Professor Stacey Missmer (Scientist Academic, USA)*  
Chair of the Endometriosis Special Interest Group of American Society for Reproductive Medicine (ASRM), Board Member of the World Endometriosis Society (WES) and the World Endometriosis Research Foundation (WERF), International Advisor for the European Society of Human Reproduction and Embryology Special Interest Group for Endometriosis and Endometrial Disorders (ESHRE SIG-EED)

*Dr Lucky Saraswat (Endopelvic Surgeon, UK)*  
Member of the British Society for Gynaecological Endoscopy (BSGE)

*Mr Ertan Saridogan (Endopelvic Surgeon, UK)*  
Executive Board Member of the European Society for Gynaecological Endoscopy (ESGE) and Past President of the British Society for Gynaecological Endoscopy (BSGE), Member of the ESHRE Guideline Group for Endometriosis

*Dr Carla Tomassetti (Endopelvic Surgeon, Belgium)*  
Past Chair of the European Society of Human Reproduction and Embryology (ESHRE) Special Interest Group for Endometriosis and Endometrial Disorders, Member of the ESHRE Guideline Group for Endometriosis

*Professor Andrew Horne (Clinical Academic, UK)*  
World Endometriosis Society (WES) Ambassador, Board Member of the Society for Endometriosis and Uterine Disorders (SEUD), European Society of Human Reproduction and Embryology (ESHRE) UK Representative, Past Chair of the ESHRE Special Interest Group for Endometriosis and Endometrial Disorders, Board Member of the British Society for Gynaecological Endoscopy (BSGE), Member of the NICE and ESHRE Guideline Groups for Endometriosis, Trustee and Medical Advisor to Endometriosis UK, and Medical Advisor to the Pelvic Pain Support Network

**Corresponding author:**

Professor Andrew Horne

**Address:** MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

**Telephone:** +44 (0)131 242 6988

**Fax number:** +44 (0)131 242 6441

**Email:** [Andrew.horne@ed.ac.uk](mailto:Andrew.horne@ed.ac.uk)

**TEXT:**

Dear Editor,

We report on work from our international taskforce established to improve the documentation of endometriosis in the upcoming 11th edition of the International Classification of Diseases (ICD-11). Our taskforce comprised representation from the World Endometriosis Society, World Endometriosis Research Foundation, European Society of Human Reproduction and Embryology, American Society for Reproductive Medicine, Society for Endometriosis and Uterine Disorders, European Society for Gynaecological Endoscopy, and British Society for Gynaecological Endoscopy.

The goal of ICD is to leverage information collected through health care systems to better understand predictors of clinical outcomes, implement data-driven strategies to improve outcomes and cost-effectiveness, and evaluate the changing impact of these strategies as health care evolves. Although new methodologies have been developed, and computing power has grown exponentially, the fundamental ingredient required for these analyses is high quality data, of which ICD coding remains a key component. For women with endometriosis, systematic ICD coding is clearly crucial to advance clinical care: it is a condition that has a high prevalence and is associated with a considerable diagnostic delay, high societal/personal burden, and no known cure.

Our taskforce noted the urgent need for improvement in the mechanics/focus of the coding process and in the structure/content of the codes for endometriosis. Classification systems for endometriosis exist including the revised American Society for Reproductive Medicine (r-ASRM) classification [1] and the Enzian classification [2,3]. There is also one validated outcomes prediction tool – the Endometriosis Fertility Index [4]. At present, no one single classification system has fully encompassed anatomic distribution and disease phenotypes nor a staging system that predicts or directs clinical outcomes such as symptom management, response to therapy, lesion and symptom recurrence, association with other disorders, or quality of life.

The nature of ICD coding lends itself to anatomical classification but even within this scope there were significant limitations with the ICD-10 classification. First and foremost, endometriosis was coded within 'noninflammatory disorders of female genital tract', which is entirely inconsistent with its current categorisation [5]. There was no clear distinction between superficial or deep disease, and there was an absence of further descriptors of location of peritoneal lesions such as the Pouch of Douglas, uterosacral ligaments, and the pelvic side wall. Peritoneal pockets were not included, nor disease affecting the bladder or ureters. Ovarian disease was not subclassified into endometrioma or superficial disease overlying the ovarian cortex, and there was no facility to reflect unilateral or bilateral disease. Furthermore, there was no specific classification for more unusual presentations, such as thoracic endometriosis and endometriosis lesions within the CNS, making estimates of prevalence challenging.

Following a consensus meeting held on 14 March 2018, we have worked closely together, following rigorous pre- and post-meeting processes, and have developed a proposal for a new ICD systematic classification of endometriosis (see Supplementary file). We believe that our proposal is both logical, inclusive of all phenotypes, and allows accurate description of anatomical distribution, within the confines of the ICD coding system. It includes specific classification of superficial and deep disease, and extended options for describing distribution. In addition, it offers structured classification of extra-abdominal lesions, particularly within the thorax, abdominal wall, central/peripheral nervous systems. ICD coding does not facilitate further description with respect to size of lesions or extent of adhesions, and so this system may have some limitations with regard to linking fertility outcomes with endometrioma size, nor can it be used to calculate Enzian or r-ASRM scores.

We submitted our proposal to WHO in June 2018 and believe that our proposed ICD classification system will facilitate the diagnostic process and lead to improved tailoring of treatments and more accurate epidemiological data.

## References

1. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril.* 1997 67(5):817-21.
2. Tuttlies F, Keckstein J, Ulrich U, Possover M, Schweppe KW, Wustlich M, Buchweitz O, Greb R, Kandolf O, Mangold R, Masetti W, Neis K, Rauter G, Reeka N, Richter O, Schindler AE, Sillem M, Terruhn V, Tinneberg HR. ENZIAN-score, a classification of deep infiltrating endometriosis. *Zentralbl Gynakol.* 2005 127(5):275-81.
3. Haas D, Shebl O, Shamiyeh A, Oppelt P. The rASRM score and the Enzian classification for endometriosis: their strengths and weaknesses. *Acta Obstet Gynecol Scand.* 2013 92(1):3-7.
4. Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. *Fertil Steril.* 2010 94(5):1609-15.
5. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. *Hum Reprod.* 2013 28(6):1552-68.

## Disclosure of interests

Andrew Horne has received research support from the MRC, NIHR, CSO, Wellbeing of Women, Roche Diagnostics, Astra Zeneca and Ferring, and has served as a consultant for AbbVie, Roche Diagnostics, Ferring and Nordic Pharma. Lone Hummelshoj has served as a consultant for AbbVie. Ertan Saridogan received honoraria from Olympus UK, Gedeon Richter and Hologic. Stacey Missmer has received research support from the NIH, AbbVie and the Marriott Family Foundations, and has served as a consultant for AbbVie and Celmatix. Lucy Whitaker, Lone Hummelshoj, Lucky Saraswat, Dominic Byrne and Carla Tomassetti have nothing to declare.

**Contribution to Authorship**

The project was coordinated by Lucy Whitaker. All other authors contributed equally to the project and the correspondence.